GLG News by Oncologists who Treat Hematologic Malignancies (US)
Articles with lock require a subscription to GLG News |
Request a free trial
May 22, 2008
Erbitux: Alot remains to be determined re: its place in NSCLCA therapy
Analysis of: Phase II trial of gemcitabine, docetaxel, and cetuximab in advanced non-small-cell lung cancer (NSCLC). | www.abstract.asco.org
Author: GLG Expert Contributor
Erbitux: Alot remains to be determined re: its place in NSCLCA therapyAnalysis of: Phase II trial of gemcitabine, docetaxel, and cetuximab in advanced non-small-cell lung cancer (NSCLC). | www.abstract.asco.org
Author: GLG Expert Contributor
" Conclusions: Cetuximab does not appear to add to treatment efficacy when combined with gemcitabine and docetaxel in advanced NSCLC. A high rate of severe cetuximab HSRs necessitated trial closure at our Nashville site." Not very promising.
May 20, 2008
Chinese Generics?? You must be kidding!
Analysis of: China Muscles In On The Generics Industry | www.pharmalot.com
Author: GLG Expert Contributor
Chinese Generics?? You must be kidding!Analysis of: China Muscles In On The Generics Industry | www.pharmalot.com
Author: GLG Expert Contributor
Low cost generics to be produced in China will lower drug costs.
May 20, 2008
Global Cancer Market: room for further growth!
Analysis of: Global market expected to drive cancer drug growth | www.therapeuticsdaily.com
Author: GLG Expert Contributor
Global Cancer Market: room for further growth!Analysis of: Global market expected to drive cancer drug growth | www.therapeuticsdaily.com
Author: GLG Expert Contributor
As world economies improve more money will be spent globally on cancer care expanding potential markets
May 19, 2008TREANDA for CLL could be a winner
Analysis of: FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma | www.pipelinereview.com
Author: Brian Abbott, Medical Director of Hematology, Big Sky Oncology
The ease of use compared to fludarabine regimens, and the superior efficacy vs chlorambucil, puts TREANDA in the sweet spot for potential front-line use in CLL.
May 19, 2008National healthcare? Better find a new pool of physicians
Analysis of: Look to England's example for ways to solve America's health-care problem | www.sltrib.com
Author: Brian Abbott, Medical Director of Hematology, Big Sky Oncology
National healthcare has again become part of the presidential election dialog, after a curious 12+ year absence. Also curious, Hillary Clinton is again center stage in the discussion. Will the outcome be different this time?
May 19, 2008Medicare: heading toward a crisis
Analysis of: Loss of Doctors Leaves Patients Waiting | www.redorbit.com
Author: Brian Abbott, Medical Director of Hematology, Big Sky Oncology
The aging population, coupled with per capita decreases in Medicare spending, threatens the entire health care system. Here's why.
May 19, 2008
The gods giveth and then takith away- Go figure.....
Analysis of: First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations | jco.ascopubs.org
Author: GLG Expert Contributor
The gods giveth and then takith away- Go figure.....Analysis of: First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations | jco.ascopubs.org
Author: GLG Expert Contributor
Two papers, the one above, and http://jco.ascopubs.org/cgi/content/full/26/15/2450 reveal somewhat conflicting data on AstraZeneca's Iressa that was until now on the "back burner" due to Genentech's Tarceva, that had better response data than Iressa in separate trials On one hand the first paper points...
May 19, 2008
Alimta (Lilly): YES!!!!
Analysis of: Lilly Drug Shown to Slow Lung Cancer | online.wsj.com
Author: GLG Expert Contributor
Alimta (Lilly): YES!!!!Analysis of: Lilly Drug Shown to Slow Lung Cancer | online.wsj.com
Author: GLG Expert Contributor
That Alimta can be effectively used after other chemotherapy in non small cell lung cancer (NSCLC) as a maintenance agent!
May 15, 2008
Novo Nordisk: Good try but recombinant activated factor VII did not reach its goal in hemorrhagic stoke
Analysis of: Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage | content.nejm.org
Author: GLG Expert Contributor
Novo Nordisk: Good try but recombinant activated factor VII did not reach its goal in hemorrhagic stokeAnalysis of: Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage | content.nejm.org
Author: GLG Expert Contributor
"In summary, rFVIIa reduced hematoma growth but did not reduce the rate of death or severe disability after intracerebral hemorrhage."
May 13, 2008
GSK: Gutsy but logical clinical trial of Tykerb v Herceptin (Genentech)
Analysis of: Glaxo Tests Tykerb vs Herceptin in Early Cancer | www.therapeuticsdaily.com
Author: GLG Expert Contributor
GSK: Gutsy but logical clinical trial of Tykerb v Herceptin (Genentech)Analysis of: Glaxo Tests Tykerb vs Herceptin in Early Cancer | www.therapeuticsdaily.com
Author: GLG Expert Contributor
Glaxo is trying to move Tykerb ahead of Herceptin in a first line/neoajuvant/adjuvant setting in Her2Neu + Breast cancer.
Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Next101 to 110 of 702
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
Why the doctor can't see you now
seattlepi.nwsource.com
Johnson & Johnson buys medical device maker
www.nytimes.com
Potassium loss from blood pressure drugs may explain higher risk of adult diabetes
www.fiercebiotech.com
McKesson Agrees To Settlement In Pricing Suits
online.wsj.com
Use of Antipsychotics in Children Poses Risks of Adverse Effects
November 26, 2008
Avastin and clots? News to me. Black box warning? Why?
November 24, 2008
Off Label Use Can Be Prevented
November 24, 2008
Gardasil will most certainly be approved for boys
November 24, 2008
Medivations's (MDVN) Dimebon - We've Seen This Movie Before
November 24, 2008